{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-076278","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.930645+00:00","generated_at":"2026-06-17T21:20:27.445042+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Wave Life Sciences reports Q4 2022 net loss $43.7M; cash runway into 2025 on $170M GSK upfront","bullets":["Q4 2022 net loss $43.7M vs $34.8M in Q4 2021; full-year 2022 net loss $161.8M vs $122.2M in 2021.","Cash and equivalents $88.5M at Dec 31, 2022; after period-end, received $170M upfront from GSK collaboration.","GSK collaboration includes up to $3.3B in potential milestones; Wave licensed WVE-006 for AATD to GSK.","WVE-006 on track for CTA submission in 2H 2023; Part B of WVE-N531 DMD study to begin in 2023 with dystrophin data in 2024.","Single-dose data from WVE-003 (HD) and WVE-004 (ALS/FTD) expected in 1H 2023; Takeda option for 50:50 co-development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-076278","json":"https://secwatch.observer/filing/0001193125-23-076278.json","markdown":"https://secwatch.observer/filing/0001193125-23-076278.md","text":"https://secwatch.observer/filing/0001193125-23-076278.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523076278/0001193125-23-076278-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523076278/d451722d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:20:27.445042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a13aa053ec88049509dbe8a113b02ed3c38fafe","claim":"Wave Life Sciences Ltd. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On March 22, 2023, Wave Life Sciences Ltd. announced its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312523076278/0001193125-23-076278-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}